Mallinckrodt and Endo, drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments.

The Ireland-domiciled company was accused of illegally paying smaller drug rebates to Medicaid than were due, as well as using a charitable foundation to cover co-pays for its Acthar Gel ...

Achieved High End of Full-Year Net Sales Guidance Range and Midpoint of Adjusted EBITDA Guidance Range Grew Full-Year Net Sales by 6.1% to $2.0 Billion, with 14.2% ...

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders ...